The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
نویسندگان
چکیده
This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8%) reported that >50.0% of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.
منابع مشابه
Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
1 raised an important question of whether respiratory syncytial virus (RSV) hospitalizations increased following decreased use of RSV immunoprophylaxis among high-risk infants and children. The authors appropriately state that their analysis of 34,000 children <24 months of age provided 80% power to detect an increase from 5 to 7.5 RSV hospitalizations per 1000 children. However, the authors di...
متن کاملA SURVEY OF RESPIRATORY SYNCYTIAL VIRUS IN CHILDREN IN THREE EDUCATIONAL AND THERAPEUTIC PEDIATRIC CENTERS IN TEHRAN
Nasopharyngeal swab samples from patients with an acute flu-like illness were evaluated for the presence of respiratory syncytial virus (RSV) from October 1996 to March 1998. The relative frequency and seasonal distribution of RSV was assessed. In addition, the virus correlated with specific clinical signs and symptoms. During the study, 268 samples were collected from children under the a...
متن کاملAuthors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
The stated hospitalization cost of $8530 (2009$) is not representative of respiratory syncytial virus (RSV) hospitalizations among palivizumab-eligible infants; it is the average cost of bronchiolitis hospitalizations among US children ,2 years.2 Using the same source, the Kids’ Inpatient Database, the average RSV hospitalization (International Classification of Diseases, Ninth Revision, Clinic...
متن کاملClarifying Costs and Benefits of Respiratory Syncytial Virus Immunoprophylaxis
The stated hospitalization cost of $8530 (2009$) is not representative of respiratory syncytial virus (RSV) hospitalizations among palivizumab-eligible infants; it is the average cost of bronchiolitis hospitalizations among US children ,2 years.2 Using the same source, the Kids’ Inpatient Database, the average RSV hospitalization (International Classification of Diseases, Ninth Revision, Clinic...
متن کاملImmunoprophylaxis of respiratory syncytial virus: global experience
Respiratory syncytial virus (RSV) infects nearly all children by age 2 years, and it causes considerable illness and death in certain high-risk pediatric populations. Historically, treatment for RSV has been symptomatic, and developing a safe and effective vaccine has been a challenge. Therefore, research efforts have turned to passive immunization as the best option to control RSV. Palivizumab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 55 شماره
صفحات -
تاریخ انتشار 2016